When Do We Treat Hypercholesterolemia?
|
|
- Sheena Boyd
- 6 years ago
- Views:
Transcription
1 Clin. Cardiol. 15 (Suppl. In>, (1992) When Do We Treat Hypercholesterolemia? w. VIRGIL BROWN, M.D. Department of Medicine, Emory University, Atlanta, Georgia, USA Summary: Although the relationships between elevated total and low-density lipoprotein (LDL) cholesterol and coronary heart disease (CHD) are relatively well established and published treatment guidelines are available, clinicians face a number of complex issues when deciding whom to treat. Specific patient characteristics and potential risk factors, of which less is known, may influence treatment decisions. In this presentation, the current guidelines for treating patients with hypercholesterolemia are reviewed and therapeutic issues that must be considered when selecting patients for treatment are identified. Key words: hypercholesterolemia, treatment, risk factors, HDL cholesterol, triglycerides lhatment Guidelines Screening and treatment guidelines for persons with elevated cholesterol have been published in the United States by the National Cholesterol Education Program (NCEP)' and in Europe by the European Atherosclerosis Society (EAS)?s3 Both sets of guidelines recommend careful evaluation for the presence of coronary heart disease (CHD) risk factors, and both promote cholesterol-lowering nutritional and pharmacologic interventions in selected individuals. The NCEP guidelines consider total cholesterol levels c 200 mg/dl(5.2 mmov1) as desirable, levels between 200 and 239 mg/dl ( mmol/l) as borderline high, and levels of 240 mg/dl (6.2 mmov1) or more as high. The NCEP guidelines, however, suggest that an assessment of low-density lipoprotein (LDL) cholesterol rather than total cholesterol be used as the factor upon which to base future treatment decisions and monitoring plans. LDL cholesterol concentrations less than 130 mg/dl(3.4 mmov1) are considered desirable, levels between 130 and 160 mg/dl( mmov1) as borderline high risk, and levels of 160 mg/ dl (4.1 mmov1) or higher as high risk. The NCEP panel recognizes that LDL cholesterol is a direct causative risk factor for CHD and, thus, the term risk is incorporated into their definitions. In scope and concept, the European guidelines are similar to those published by the NCEP; however, the former differ in the absolute definitions applied to acceptable or desirable total cholesterol levels. For example, the European guidelines define those with total cholesterol between 200 and 250 mg/dl ( mmol/l) and triglycerides c200 mg/dl as in need of dietary or lifestyle changes. Unlike the NCEP guidelines, the European guidelines recommend assessing triglyceride concentrations to fully characterize the need for lipid-lowering interventions. The NCEP and the EAS also consider CHD risk factors and history of CHD in their treatment recommendations. CHD Risk Factors In addition to assessments of elevated total and LDL cholesterol (and triglycerides in Europe), guidelines for intervention are influenced by a variety of patient-specific risk factors. Known and evolving CHD risk factors and the application of these to treatment of high total cholesterol are reviewed in the following sections. LDL Cholesterol Address for reprints: W. Virgil Brown, M.D. Professor of Medicine Emory University School of Medicine 1400 Clifton Road Po Drawer AG, 201 Woodruff Memorial Building Atlanta, GA 30322, USA In the United States, almost without exception, we vigorously treat individuals with LDL cholesterol greater than 220 mg/dl(5.7 mmol/l), which is considered severe hypercholesterolemia (Fig. 1). The NCEP panel also recommends considering treatment for individuals with LDL cholesterol higher than 190 mg/dl (4.9 rnmov1) who are without CHD or other attributable risk factors. This is not
2 W.V. Brown: When to treat hypercholesterolemia LDL cholesterol Moderate hypercholesterolemia Severe hypercholesterolemia RG. 1 Candidates for lipid-lowering drug therapy according to National Cholesterol Education Program (NCEP) guidelines (from Ref. 1). to imply that all persons with LDL cholesterol higher than 190 mg/dl should be on pharmacologic treatment, but rather, it is a recommendation that clinicians should consider drug therapy if LDL cholesterol remains higher than 190 mddl(4.9 mmol/l) after lifestyle changes (e.g., dietary restrictions, exercise, weight loss) have been implemented. The NCEP guidelines state that drug therapy is appropriate for persons with LDL cholesterol levels of 160 mg/dl(4.1 mmovi) or greater in the presence of CHD or two CHD risk factors. Clinical judgment should be used when LDL cholesterol is in the borderline high-risk category [ mg/dl ( mmolfl)]; drug treatment should not be the first step, but dietary and lifestyle changes certainly are appropriate. It is of interest that, over the last several years, we have seen more aggressive intervention in certain patients. In some clinical trials, mean reductions in LDL cholesterol to less than 100 mddl(2.6 mmov1) have provided clear benefit in terms of angiographically defined CHD4 and morbid it^.^ Particularly in patients with overt CHD, the appropriate range of LDL cholesterol for intervention and the appropriate target value are being reconsidered in the United States and around the world. Other Known CHD Risk Factors In addition to LDL cholesterol, a number of CHD risk factors have been e~tablished.~ For persons with LDL cholesterol between 160 and 190 mddl( mmovi), the presence of two (or more) of these CHD risk factors demands that the patient is classified as being at high risk. Known CHD risk factors include male gender, a family history of premature CHD, smoking more than 10 cigarettes a day, high blood pressure, low high-density lipoprotein (HDL) cholesterol [<35 mg/dl(o.9 mmovi)], diabetes, a history of cerebral vascular disease (or at least disease in other vascular beds), and obesity. Abdominal obesity was not considered originally, but evidence is evolving that the distribution of body fat plays a role as important as total obesity, particularly in persons who are mildly to moderately overweight. As clinicians, we appreciate that very few of these CHD risk factors can be assessed on an absolute basis and that most must be considered as a continuous risk function. This is especially true for high blood pressure, low HDL cholesterol, and diabetes. For example, does a woman with diabetes have the same risk for CHD as a male with diabetes; or should diabetes in a woman be considered only as a single risk factor? In other words, the quality of the risk factor as well as its presence or absence must be considered. Candidates for Drug Therapy Using our understanding of known CHD risk factors, we can identify a tremendous number of individuals who are candidates for treatment of elevated cholesterol. A calculation made by the Second National Health and Nutrition Examination Survey (NHANES 11) based on the NCEP guidelines estimated that 57 million Americans between the ages of 20 and 74 years are eligible for treatment. These calculations are made using the strict total cholesterol cutpoints recommended by the NCEP. However, if we examine 12-year follow-up data from the Multiple Risk Factor Intervention Trial (MRFIT)? which include CHD deaths in terms of actual cholesterol distributions, 22.2% of all CHD deaths occurred in men who had total cholesterol less than 202 mg/dl; 8.3% of these deaths occurred in men with baseline total cholesterol less than 182 mg/dl. In fact, more than 82% of the entire cohort had baseline total cholesterol levels higher than 182 mg/dl and, as shown in Table I and Figure 2, a clear and statistically significant risk for CHD events is apparent at this cholesterol concentration. Recently, data from other studies support this observation that CHD events occur in a substantial proportion of persons with previously considered desirable total cholesterol. For example, in the Physicians Health Study, 33% of all myocardial infarctions occurred in individuals who had baseline total cholesterol levels c200 mg/dl (5.2 mmom). Other risk factors continue to play an important
3 m-12 Clin. Cardiol. Vol. 15 (Suppl. HI),November 1992 TABLE I CHD death rates (per 10,OOO person-years) and adjusted relative risk estimates by quintile of serum cholesterol for white men (age years) screened in the MRFIT Serum cholesterol quintile mg/dl (mrnov1) Deaths Crude rate Adjusted RR 1 c182(4.7) o ( ) a ( ) a ( ) " (6.3) ga a p c 0.05 for comparison with first quintile. Abbreviurions: CHD = coronary heart disease; MRFIT = Multiple Risk Factor Intervention Trial; RR = relative risk. Source: Modified from Neaton et al., Arch Intern Med 152,5644 (1992), copyright 1992, American Medical Association, Ref. 6. role even in those with desirable cholesterol levels. Clinical investigations should be directed toward identifying other CHD risk factors. It should be noted that abnormalities in the plasma lipoproteins may contribute to vascular risk without elevating total blood cholesterol above 200 mg/dl and this is an important area for further study. Secondary Prevention and Regression Studies Many recent trials have addressed the issue of treating hypercholesterolemic individuals who have overt CHD.8 Although we are seeing remarkable results, the question remains as to whether we should be more aggressive than called for by the NCEP guidelines. Interventional efforts to lower elevated cholesterol in individuals who have established CHD have been demonstrated to be beneficial. According to results of the Program on Surgical Control of Hyperlipidemia (POSCH) study5 and the Familial Hypercholesterolemia study conducted at the University of California in San Francisco? drug plus dietary intervention clearly and significantly reduced atherosclerotic lesion progression. These treatments increased the probability of regression; new lesions were reduced in native arteries and in grafts. These benefits were observed in groups with mean total cholesterol reduced below 185 mg/dl, which is lower than that suggested by the NCEP guidelines. According to the Cholesterol Lowering Atherosclerosis Study (CLAS)4 and the Familial Atherosclerosis Treatment Study (FATS),l0 aggressive lipid regulation should be initiated in anyone who has coronary artery bypass grafts; angioplasty certainly could be considered another indication. Evolving Patient Selection Issues In addition to known CHD risk factors, other patient selection issues must be considered when deciding who is an appropriate candidate for cholesterol-lowering interventions. HDL Cholesterol High-density lipoprotein (HDL) is a powerful independent inverse predictor of CHD risk." Some individuals with low total cholesterol and CHD may have low HDL cholesterol that is linked with high triglyceride levels. The NCEP guidelines as they now exist promote HDL choles (120) (140) (160) (180) (200) (220) (240) (260) (280) (300) (320) (340) Serum cholesterol, mmol/l (mg/dl) Numberofmen: ,118 37,514 58,720 69,343 56,106 37,619 21, Numberofdeaths: FIG. 2 Age-adjusted coronary heart disease (CHD) death rates per 10,OOO person-years by level of serum cholesterol for men screened in the Multiple Risk Factor Intervention Trial. [Reprinted with permission from Neaton et al., Arch Intern Med 152, (1992), Copyright 1992, American Medical Association, Ref. 61.
4 W.V. Brown: When to treat hypercholesterolemia III- 13 terol measurement, but state that we should only consider HDL problematic when it is less than 35 mgm(o.9 mmom). It is interesting that low HDL cholesterol may represent a heterogeneous group of disorders; some people with low HDL cholesterol appear to be at high risk for CHD while others are not. Well-designed clinical trials are needed that specifically address the issue of raising HDL cholesterol and that eliminate (or reduce) potential confounding factors. For example, studies using drug interventions that affect only HDL cholesterol without causing significant changes in LDL cholesterol or triglyceride concentrations might answer some of these questions. We also need to improve our methods for measuring HDL cholesterol to reduce laboratory variability. This would make HDL cholesterol values more useful in the clinic. Physician awareness of the protective benefits of HDL cholesterol is increasing; however, a number of unanswered questions still must be addressed. Evidence exists that raising HDL is beneficial and, although the data are incomplete, they must not be ignored. Results from the Helsinki Heart StudyI2 and the Lipid Research Clinics Tria indicate the beneficial effects of increasing HDL cholesterol levels concomitant with a reduction in LDL cholesterol. 'higlycerides Elevated triglyceride levels are generally associated with an increased risk of CHD. There is a known link between elevated triglyceride levels and other risk factors, specifically elevated LDL cholesterol and decreased HDL cholesterol. It is not clear, however, whether the triglyceride metabolic problem is causally related to CHD through chylomicron remnant metabolism or causally related as a result of disturbances that are linked to LDL and HDL changes.15 In other words, are triglycerides directly atherogenic or are they metabolic markers for the presence of other conditions such as diabetes (e.g., the derangement caused by glucose metabolic defects that are fully expressed only in diabetes but perhaps more subtly expressed in insulin resistance without diabetes), low HDL, or obesity? Currently, we have few answers but investigations are ongoing. Patient Populations Elderly. The need for definitive guidelines for treating the elderly patient with high cholesterol is becoming more apparent as the elderly population continues to grow. Currently, we do not have enough hard data from clinical trials in the elderly to guide us with respect to therapeutic intervention. We have suggestive evidence that cholesterol lowering is beneficial in reducing the incidence of CHD and stroke in the elderly. For example, in the older population of patients in the Lipid Research Clinics Trial13J4, the benefits in persons who were well into their sixth decade by the close of the trial were as great as in those who entered the trial at a younger age. A pilot study specifically for the elderly, the Cholesterol Reduction In Seniors Program (CRISP), has been initiated. This study will examine the effects of an HMG-CoA reductase inhibitor on primary CHD prevention in persons older than 65 years of age. However, it will be several years, perhaps a decade, before we will have clear-cut answers on the benefit of lowering cholesterol in this population. Epidemiologic studies indicate that total cholesterol continues to be an important risk factor in persons up to 85 years of age. There are less data on the relationships between LDL and HDL cholesterol in the elderly, but both appear to be related to CHD risk as in younger populations. Women. Like the elderly, our knowledge about the most appropriate lipid-lowering interventions for hypercholesterolemic women is incomplete. In women as in men, we know that high cholesterol levels are predictive of CHD risk.i6 Furthermore, evidence from at least one trial has shown that very aggressive pharmacologic intervention with three drugs [colestipol, niacin (nicotinic acid), and lovastatin] has produced atherosclerotic lesion regression in women with familial hypercholesterolemia? Concomitant Drug Therapy Patients with high cholesterol are likely to have concomitant medical conditions (e.g., hypertension, diabetes, previous myocardial infarction, or angina pectoris) for which other medications have been prescribed. Clearly, some of the medications may have a positive impact, but others may have a negative effect on cardiovascular risk. A classic example is thiazide diuretics; these drugs reduce blood pressure but in fact provide no evidence of CHD reduction and demonstrate considerable evidence that damage may be done. Exercise A moderate exercise program, in conjunction with sound nutritional advice, is often promoted by physicians not only for their overweight patients, but to all patients as a part of a healthy lifestyle. How exercise actually lowers CHD risk is not known, although potential benefits to be gained by moderate exercise (under a physician's routine monitoring) may include weight loss, stress reduction, increased HDL cholesterol, and possibly improvement in related medical conditions, such as diabetes or hypertension. Additional data, such as whether to approach hypercholesterolemic patients who exercise differently from sedentary patients, are needed. Conclusions Although U.S. and European guidelines direct us toward proper screening and treatment approaches for hypercho-
5 III-14 Clin. Cardiol. Vol. 15 (Suppl. 111), November 1992 lesterolemic individuals, clinicians face a number of unresolved issues that relate to the large number of patient-specific risk factors that may accelerate the impact of LDL cholesterol on developing or existing CHD. Many of these risk factors are well established: elevated LDL cholesterol, male gender, cigarette smoking, high blood pressure, and diabetes are included in this group. Other evolving issues that must be considered include assessments of HDL cholesterol, elevated triglycerides, postprandial lipoproteins, and whether more specific guidelines for lipid-lowering drug treatment are needed for women and the elderly. References The Expert Panel: Report of the National Cholesterol Education Program Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults. Arch Intern Med 148,36-69 (1988) Study Group, European Atherosclerosis Society: The recognition and management of hyperlipidaemia in adults: A policy statement of the European Atherosclerosis Society. Eur Heart J 9, (1988) Study Group, European Atherosclerosis Society: Strategies for the prevention of coronary heart disease: A policy statement of the European Atherosclerosis Society. Eur Heart J 8, (1987) Blankenhorn DH, Nessim SA, Johnson RL, Sanmarco ME, Azen SP, Cashin-Hemphill L: Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. J Am Med Assoc 257, (1987) Buchwald H, Varco RL, Matts JP, Long JM, Fitch LL, Campbell GS, Pearce MB, Yellin AE, Edmiston WA, Smink RD Jr, Sawin HS Jr, Campos CT, Hansen BJ, Tuna N, Karnegis JN, Sanmarco ME, Amplatz K, Casteneda-Zuniga WR, Hunter DW, Bissett JK, Weber FJ, Stevenson JW, Leon AS, Chalmers TC, and the POSCH Group: Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia: Report of the Program on the Surgical Control of the Hyperlipidemias (POSCH). N Engl J Med 323, (1990) 6. Neaton JD, Wentworth D, for the Multiple Risk Factor Intervention Trial Research Group: Serum cholesterol, blood pressure, cigarette smoking, and death from coronary heart disease. Arch Intern Med 152,56-64 (1992) 7. Steering Committee of the Physicians Health Study Research Group: Final report on the aspirin component of the ongoing Physicians Health Study. N Engl J Med 321, (1989) 8. Rossouw JE, Lewis B, Rifkind BM: The value of lowering cholesterol after myocardial infarction. N Engl J Med 323, (1990) 9. Kane JP, Malloy MJ, Ports TA, Phillips NR, Diehl JA, Have1 RJ: Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens. J Am Med Assoc 264, (1990) 10. Brown G, Albers JJ, Fisher LD, Schaefer SM, Lin J-T, Kaplan C, Zhao X-Q, Bisson BD, Fitzpatrick VF, Dodge HT Regression of coronary artery disease as a result of intensive lipidlowering therapy in men with high levels of apolipoprotein B. N Engl JMed 323, (1990) 11. Abbott RD, Wilson PWF, Kannel WE%, Castelli WP: High-density lipoprotein cholesterol, total cholesterol screening, and myocardial infarction. Arteriosclerosis 8, (1988) 12. Frick MH, Elo 0, Haapa K, Heinonen OP, Heinsalmi P, Helo P, Huttunen JK, Kaitaniemi P, Koskinen P, Manninen V, MaenpG H, Malkonen M, MXnttiiri M, Norola S, Pastemack A, Pikkarainen J, Romo M, Sjoblom T, Nikkila EA: Helsinki Heart Study: Primary prevention trial with gemfibrozil in middleaged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 317, (1987) 13. Lipid Research Clinics Program: The Lipid Research Clinics Coronary Primary Prevention Trial results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAm Med Assoc 251, (1984) 14. Lipid Research Clinics Program: The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. JAm Med Assoc 251, (1984) 15. Grundy SM, Vega GL: Two different views of the relationship of hypertriglyceridemia to coronary heart disease. Arch Intern Med 152,28-34 (1992) 16. Wilson PW, Garrison RJ, Castelli WP, Feinleib M, McNamara PM, Kannel WB: Prevalence of coronary heart disease in the Framingham Offspring Study: Role of lipoprotein cholesterols. Am J Cardiol46, (1980)
Cholesterol and Cardiovascular Disease: How Strong is the Evidence?
Clin. Cardiol. 15 (Suppl. 111), 111-2-111-7 (1992) Cholesterol and Cardiovascular Disease: How Strong is the Evidence? JOHN C. LAROSA, M.D., F.A.C.P. Lipid Research Clinic, Department of Medicine and Health
More informationThe investigation of serum lipids and prevalence of dyslipidemia in urban adult population of Warangal district, Andhra Pradesh, India
eissn: 09748369, www.biolmedonline.com The investigation of serum lipids and prevalence of dyslipidemia in urban adult population of Warangal district, Andhra Pradesh, India M Estari, AS Reddy, T Bikshapathi,
More informationAndrew Cohen, MD and Neil S. Skolnik, MD INTRODUCTION
2 Hyperlipidemia Andrew Cohen, MD and Neil S. Skolnik, MD CONTENTS INTRODUCTION RISK CATEGORIES AND TARGET LDL-CHOLESTEROL TREATMENT OF LDL-CHOLESTEROL SPECIAL CONSIDERATIONS OLDER AND YOUNGER ADULTS ADDITIONAL
More informationScreening for Total Cholesterol
1287 Screening for Total Cholesterol Do the National Cholesterol Education Program's Recommendations Detect Individuals at High Risk of Coronary Heart Disease? Trudy L. Bush, PhD, MHS, and Denise Riedel,
More informationHow would you manage Ms. Gold
How would you manage Ms. Gold 32 yo Asian woman with dyslipidemia Current medications: Simvastatin 20mg QD Most recent lipid profile: TC = 246, TG = 100, LDL = 176, HDL = 50 What about Mr. Williams? 56
More informationPlasma lipids and cardiovascular risk: a POSCH report
Atherosclerosis 154 (2001) 221 227 www.elsevier.com/locate/atherosclerosis Plasma lipids and cardiovascular risk: a POSCH report Henry Buchwald a, *, James R. Boen b, Phuong A. Nguyen a, Stanley E. Williams
More information( Diabetes mellitus, DM ) ( Hyperlipidemia ) ( Cardiovascular disease, CVD )
005 6 69-74 40 mg/dl > 50 mg/dl) (00 mg/dl < 00 mg/dl(.6 mmol/l) 30-40% < 70 mg/dl 40 mg/dl 00 9 mg/dl fibric acid derivative niacin statin fibrate statin niacin ( ) ( Diabetes mellitus,
More informationRosuvastatin: An Effective Lipid Lowering Drug against Hypercholesterolemia
ISPUB.COM The Internet Journal of Cardiovascular Research Volume 3 Number 1 Rosuvastatin: An Effective Lipid Lowering Drug against Hypercholesterolemia V Save, N Patil, G Rajadhyaksha Citation V Save,
More informationMOLINA HEALTHCARE OF CALIFORNIA
MOLINA HEALTHCARE OF CALIFORNIA HIGH BLOOD CHOLESTEROL IN ADULTS GUIDELINE Molina Healthcare of California has adopted the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel
More informationDiet and Cholesterol Guidelines and Coronary Heart Disease*
JACC Vol. 13, No. 2 February 1989:503-7 503 Diet and Cholesterol Guidelines and Coronary Heart Disease* ANTONIO M. GOTTO, JR., MD, DPHIL Houston, Texas It is important to have public debate on critical
More informationNearly 62 million people in the. ... REPORTS... New Therapeutic Options in the National Cholesterol Education Program Adult Treatment Panel III
... REPORTS... New Therapeutic Options in the National Cholesterol Education Program Adult Treatment Panel III Robert L. Talbert, PharmD Abstract Coronary heart disease (CHD) is a common, costly, and undertreated
More informationNew Features of the National Cholesterol Education Program Adult Treatment Panel III Lipid-Lowering Guidelines
Clin. Cardiol. Vol. 26 (Suppl. III), III-19 III-24 (2003) New Features of the National Cholesterol Education Program Adult Treatment Panel III Lipid-Lowering Guidelines H. BRYAN BREWER, JR, M.D. Molecular
More informationSTATIN UTILIZATION MANAGEMENT CRITERIA
STATIN UTILIZATION MANAGEMENT CRITERIA DRUG CLASS: HMG Co-A Reductase Inhibitors & Combinations Agents which require prior review: Advicor (niacin extended-release/lovastatin) Crestor (rosuvastatin)(5mg,10mg,
More informationPIEDMONT ACCESS TO HEALTH SERVICES, INC. Guidelines for Screening and Management of Dyslipidemia
PIEDMONT ACCESS TO HEALTH SERVICES, INC. Policy Number: 01-09-021 SUBJECT: Guidelines for Screening and Management of Dyslipidemia EFFECTIVE DATE: 04/2008 REVIEWED/REVISED: 04/12/10, 03/17/2011, 4/10/2012,
More informationThreshold Level or Not for Low-Density Lipoprotein Cholesterol
... SYMPOSIA PROCEEDINGS... Threshold Level or Not for Low-Density Lipoprotein Cholesterol Based on a debate between Philip J. Barter, MD, PhD, FRACP, and Frank M. Sacks, MD Debate Summary As drugs, such
More informationApplicability of Cholesterol-Lowering Primary Prevention Trials to a General Population
Applicability of Cholesterol-Lowering Primary Prevention Trials to a General Population The Framingham Heart Study ORIGINAL INVESTIGATION Donald M. Lloyd-Jones, MD; Christopher J. O Donnell, MD, MPH; Ralph
More informationMedical evidence suggests that
COMBINATION THERAPY TO ACHIEVE LIPID GOALS David G. Robertson, MD* ABSTRACT Coronary heart disease (CHD) remains the leading cause of death in the United States despite recent advances in treatment and
More informationCardiovascular Complications of Diabetes
VBWG Cardiovascular Complications of Diabetes Nicola Abate, M.D., F.N.L.A. Professor and Chief Division of Endocrinology and Metabolism The University of Texas Medical Branch Galveston, Texas Coronary
More informationRaising high-density lipoprotein cholesterol: where are we now?
European Heart Journal Supplements (23) 5 (Supplement D), D17 D25 Raising high-density lipoprotein cholesterol: where are we now? Baylor College of Medicine, Houston, Texas, U.S.A. KEYWORDS Apolipoprotein;
More informationSafety profile of atorvastatin-treated patients with low LDL-cholesterol levels
Atherosclerosis 149 (2000) 123 129 www.elsevier.com/locate/atherosclerosis Safety profile of atorvastatin-treated patients with low LDL-cholesterol levels Rebecca G. Bakker-Arkema *, James W. Nawrocki,
More informationDiabetic Dyslipidemia
Diabetic Dyslipidemia Dr R V S N Sarma, M.D., (Internal Medicine), M.Sc., (Canada), Consultant Physician Cardiovascular disease (CVD) is a significant cause of illness, disability, and death among individuals
More informationKatsuyuki Nakajima, PhD. Member of JCCLS International Committee
Katsuyuki Nakajima, PhD Member of JCCLS International Committee Visiting Professor and Scientist Tufts University, Boston, MA & Framingham Offspring Study, Framingham, MA August 20 th, 2011, Tokyo Framingham
More informationOptimizing risk assessment of total cardiovascular risk What are the tools? Lars Rydén Professor Karolinska Institutet Stockholm, Sweden
Optimizing risk assessment of total cardiovascular risk What are the tools? Lars Rydén Professor Karolinska Institutet Stockholm, Sweden Cardiovascular Disease Prevention (CVD) Three Strategies for CVD
More informationAccelerated atherosclerosis begins years prior to the diagnosis of diabetes
Joslin Diabetes Forum 211: Optimizing Care for the Practicing Clinician Risk for atherosclerosis is 2 4 times greater in patients with diabetes CVD accounts for 65% of diabetic mortality >5% of patients
More informationTHE PAST DECADE HAS WITnessed
SPECIAL COMMUNICATION Clinical Goals and Performance Measures for Cholesterol Management in Secondary Prevention of Coronary Heart Disease Thomas H. Lee, MD James I. Cleeman, MD Scott M. Grundy, MD Clayton
More informationnicotinic acid 375mg, 500mg, 750mg, 1000mg modified release tablet (Niaspan ) No. (93/04) Merck
Scottish Medicines Consortium Resubmission nicotinic acid 375mg, 500mg, 750mg, 1000mg modified release tablet (Niaspan ) No. (93/04) Merck New formulation 6 January 2006 The Scottish Medicines Consortium
More informationThe updated guidelines from the National
BEYOND NCEP ATP III: LESSONS LEARNED AND FUTURE DIRECTIONS * Benjamin J. Ansell, MD, FACP ABSTRACT The National Cholesterol Education Program (NCEP) Third Adult Treatment Panel (ATP III) guidelines provide
More informationThe new guidelines issued in PRESENTATIONS... Future Outlook: Changing Perspectives on Best Practice
... PRESENTATIONS... Future Outlook: Changing Perspectives on Best Practice Based on a presentation by Daniel J. Rader, MD Presentation Summary The guidelines recently released by the National Cholesterol
More informationThe American Diabetes Association estimates
DYSLIPIDEMIA, PREDIABETES, AND TYPE 2 DIABETES: CLINICAL IMPLICATIONS OF THE VA-HIT SUBANALYSIS Frank M. Sacks, MD* ABSTRACT The most serious and common complication in adults with diabetes is cardiovascular
More informationReducing low-density lipoprotein cholesterol treating to target and meeting new European goals
European Heart Journal Supplements (2004) 6 (Supplement A), A12 A18 Reducing low-density lipoprotein cholesterol treating to target and meeting new European goals University of Sydney, Sydney, NSW, Australia
More informationORIGINAL INVESTIGATION
ORIGINAL INVESTIGATION Effective Lipid Modification by Partial Ileal Bypass Reduced Long-term Coronary Heart Disease Mortality and Morbidity: Five-Year Posttrial Follow-up Report From the POSCH Henry Buchwald,
More informationPreventing Myocardial Infarction in the Young Adult in the First Place: How Do the National Cholesterol Education Panel III Guidelines Perform?
Journal of the American College of Cardiology Vol. 41, No. 9, 2003 2003 by the American College of Cardiology Foundation ISSN 0735-1097/03/$30.00 Published by Elsevier Inc. doi:10.1016/s0735-1097(03)00187-6
More informationLIPIDS AND CHOLESTEROL - RISK FACTORS TO A POLICE UNIT FROM BRASOV
Bulletin of the Transilvania University of Braşov Series VI: Medical Sciences Vol. 4 (53) No. 2-2011 LIPIDS AND CHOLESTEROL - RISK FACTORS TO A POLICE UNIT FROM BRASOV C. DOBRESCU 1 I. MOLEAVIN 1 Abstract:
More informationThe Metabolic Syndrome: Is It A Valid Concept? YES
The Metabolic Syndrome: Is It A Valid Concept? YES Congress on Diabetes and Cardiometabolic Health Boston, MA April 23, 2013 Edward S Horton, MD Joslin Diabetes Center Harvard Medical School Boston, MA
More informationHyperlipidemia. Prepared by : Muhannad Mohammed Supervisor professor : Dr. Ahmed Yahya Dallalbashi
Hyperlipidemia Prepared by : Muhannad Mohammed Supervisor professor : Dr. Ahmed Yahya Dallalbashi Outline The story of lipids Definition of hyperlipidemia Classification of hyperlipidemia Causes of hyperlipidemia
More informationThe Framingham Coronary Heart Disease Risk Score
Plasma Concentration of C-Reactive Protein and the Calculated Framingham Coronary Heart Disease Risk Score Michelle A. Albert, MD, MPH; Robert J. Glynn, PhD; Paul M Ridker, MD, MPH Background Although
More informationRECOGNITION OF THE METABOLIC SYNDROME
THE METABOLIC SYNDROME IN CLINICAL PRACTICE Michael H. Davidson, MD* ABSTRACT Patients with the metabolic syndrome remain at significantly elevated risk of morbidity and mortality associated with coronary
More informationDietary therapy for different forms of hyperlipoproteinemia
CHOLESTEROL AND CARDIOVASCULAR DISEASE Dietary therapy for different forms of hyperlipoproteinemia SCOTr M. GRUNDY, M.D., PH.D. ABSTRACT Diet is the first line of therapy for hypercholesterolemia. The
More informationEstablished Risk Factors for Coronary Heart Disease (CHD)
Getting Patients to Make Small Lifestyle Changes That Result in SIGNIFICANT Improvements in Health - Prevention of Diabetes and Obesity for Better Health Maureen E. Mays, MD, MS, FACC Director ~ Portland
More informationAltered concentrations of blood plasma
C O N S E N S U S S T A T E M E N T Detection and Management of Lipid Disorders in Diabetes Altered concentrations of blood plasma lipoproteins are powerful predictors of coronary heart disease (CHD) and
More informationOn May 2001, the Third Adult
THE RISK OF DIABETES: CAN WE IMPACT CHD THROUGH THE ATP III CHOLESTEROL GUIDELINES? * Based on a presentation given by Steven M. Haffner, MD, MPH ABSTRACT Diabetes has been recognized among diabetologists
More informationSTATINS FOR PAD Long - term prognosis
STATINS FOR PAD Long - term prognosis Prof. Pavel Poredos, MD, PhD Department of Vascular Disease University Medical Centre Ljubljana Slovenia DECLARATION OF CONFLICT OF INTEREST No conflict of interest
More information4/7/ The stats on heart disease. + Deaths & Age-Adjusted Death Rates for
+ Update on Lipid Management Stacey Gardiner, MD Assistant Professor Division of Cardiovascular Medicine Medical College of Wisconsin + The stats on heart disease Over the past 10 years for which statistics
More informationDYSLIPIDAEMIC PATTERN OF PATIENTS WITH TYPE 2 DIABETES MELLITUS. Eid Mohamed, Mafauzy Mohamed*, Faridah Abdul Rashid
Malaysian Journal of Medical Sciences, Vol. 11, No. 1, January 2004 (44-51) ORIGINAL ARTICLE DYSLIPIDAEMIC PATTERN OF PATIENTS WITH TYPE 2 DIABETES MELLITUS Eid Mohamed, Mafauzy Mohamed*, Faridah Abdul
More informationthe U.S. population, have some form of cardiovascular disease. Each year, approximately 6 million hospitalizations
Cardioprotection: What is it? Who needs it? William B. Kannel, MD, MPH From the Department of Preventive Medicine and Epidemiology, Evans Department of Clinical Research, Boston University School of Medicine,
More informationThe Best Lipid Fraction for the Prediction of the Population at Risk of Atherothrombotic Disease. William E. Feeman, Jr., M.D.
The Best Lipid Fraction for the Prediction of the Population at Risk of Atherothrombotic Disease William E. Feeman, Jr., M.D. 640 South Wintergarden Road Bowling Green, Ohio 43402 Phone 419-352-4665 Fax
More informationATP IV: Predicting Guideline Updates
Disclosures ATP IV: Predicting Guideline Updates Daniel M. Riche, Pharm.D., BCPS, CDE Speaker s Bureau Merck Janssen Boehringer-Ingelheim Learning Objectives Describe at least two evidence-based recommendations
More information1. Which one of the following patients does not need to be screened for hyperlipidemia:
Questions: 1. Which one of the following patients does not need to be screened for hyperlipidemia: a) Diabetes mellitus b) Hypertension c) Family history of premature coronary disease (first degree relatives:
More informationSection Editor Mason W Freeman, MD
Official reprint from UpToDate www.uptodate.com 2015 UpToDate The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek
More informationHIGH LDL CHOLESTEROL IS NOT AN INDEPENDENT RISK FACTOR FOR HEART ATTACKS AND STROKES
HIGH LDL CHOLESTEROL IS NOT AN INDEPENDENT RISK FACTOR FOR HEART ATTACKS AND STROKES A study published in the British Medical Journal shows that not only is high LDL cholesterol not a risk factor for all-caused
More informationManagement of Hyperlipidaemia in General Practice
Management of Hyperlipidaemia in General Practice Pages with reference to book, From 285 To 287 Waris Qidwai ( Family Medicine Division, Department of Community Health Sciences, The Aga Khan University,
More informationCurrent Cholesterol Guidelines and Treatment of Residual Risk COPYRIGHT. J. Peter Oettgen, MD
Current Cholesterol Guidelines and Treatment of Residual Risk J. Peter Oettgen, MD Associate Professor of Medicine Harvard Medical School Director, Preventive Cardiology Beth Israel Deaconess Medical Center
More informationSee p Downloaded from by on January 18, 2019 The beneficial effects of cholesterol-lowering therapy for the
Relationship Between Plasma LDL Concentrations During Treatment With Pravastatin and Recurrent Coronary Events in the Cholesterol and Recurrent Events Trial Frank M. Sacks, MD; Lemuel A. Moyé, MD, PhD;
More informationCost-effectiveness of pravastatin for primary prevention of coronary artery disease in Japan Nagata-Kobayashi S, Shimbo T, Matsui K, Fukui T
Cost-effectiveness of pravastatin for primary prevention of coronary artery disease in Japan Nagata-Kobayashi S, Shimbo T, Matsui K, Fukui T Record Status This is a critical abstract of an economic evaluation
More informationGuidelines for Management of Dyslipidemia and Prevention of Cardiovascular Disease
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AMERICAN COLLEGE OF ENDOCRINOLOGY Guidelines for Management of Dyslipidemia and Prevention of Cardiovascular Disease Writing Committee Chair: Paul S. Jellinger,
More informationMacrovascular Management. What s next beyond standard treatment?
Macrovascular Management What s next beyond standard treatment? Are Lifestyle Modifications Still Relevant in Diabetic Patients? Diet Omega-6 and omega-3 fatty acids have been shown to improve CVD risk
More informationInfluence of Baseline Lipids on Effectiveness of Pravastatin in the CARE Trial
JACC Vol. 33, No. 1 January 1999:125 30 125 Influence of Baseline Lipids on Effectiveness of Pravastatin in the CARE Trial MARC A. PFEFFER, MD, PHD, FACC, FRANK M. SACKS, MD, LEMUEL A. MOYÉ, MD, PHD,*
More informationReview of guidelines for management of dyslipidemia in diabetic patients
2012 international Conference on Diabetes and metabolism (ICDM) Review of guidelines for management of dyslipidemia in diabetic patients Nan Hee Kim, MD, PhD Department of Internal Medicine, Korea University
More informationAssessing Cardiovascular Risk to Optimally Stratify Low- and Moderate- Risk Patients. Copyright. Not for Sale or Commercial Distribution
CLINICAL Viewpoint Assessing Cardiovascular Risk to Optimally Stratify Low- and Moderate- Risk Patients Copyright Not for Sale or Commercial Distribution By Ruth McPherson, MD, PhD, FRCPC Unauthorised
More informationDYSLIPIDEMIA PHARMACOLOGY. University of Hawai i Hilo Pre- Nursing Program NURS 203 General Pharmacology Danita Narciso Pharm D
DYSLIPIDEMIA PHARMACOLOGY University of Hawai i Hilo Pre- Nursing Program NURS 203 General Pharmacology Danita Narciso Pharm D 1 LEARNING OBJECTIVES Know normal cholesterol levels Understand what the role
More informationCoronary heart disease (CHD) has. Clearfield The National Cholesterol Education Program Adult Treatment Panel III guidelines
the osteopathic physician. The treatment approach involves therapeutic lifestyle changes with diet, exercise, and weight loss. It requires regular, careful monitoring of serum cholesterol levels. The new
More informationHDL-C. J Jpn Coll Angiol, 2008, 48: NIPPON DATA80, MEGA study, JELIS, dyslipidemia, risk assessment chart
Online publication March 25, 2009 48 6 2007 2007 HDL-C LDL-C HDL-C J Jpn Coll Angiol, 2008, 48: 463 470 NIPPON DATA80, MEGA study, JELIS, dyslipidemia, risk assessment chart 1987 NIPPON DATA80 Iso 10 MRFIT
More informationCardiovascular Disease
8 High-Density Lipoprotein Cholesterol and Cardiovascular Disease Four Prospective American Studies David J. Gordon, MD, PhD, Jeffrey L. Probstfield, MD, Robert J. Garrison, MS, James D. Neaton, PhD, William
More informationLearning Objectives. Patient Case
Joseph Saseen, Pharm.D., FASHP, FCCP, BCPS Professor and Vice Chair, Department of Clinical Pharmacy University of Colorado Anschutz Medical Campus Learning Objectives Identify the 4 patient populations
More informationFamilial hypercholesterolaemia in children and adolescents
Familial hypercholesterolaemia in children and adolescents Rationale and recommendations for early identification and treatment European Atherosclerosis Society Consensus Panel Slide deck adapted from:
More informationHigh Density Lipoprotein Cholesterol and Mortality
High Density Lipoprotein Cholesterol and Mortality The Framingham Heart Study Peter W.F. Wilson, Robert D. Abbott, and William P. Castelli In 12 years of follow-up for 2748 Framingham Heart Study participants
More informationGuidelines on cardiovascular risk assessment and management
European Heart Journal Supplements (2005) 7 (Supplement L), L5 L10 doi:10.1093/eurheartj/sui079 Guidelines on cardiovascular risk assessment and management David A. Wood 1,2 * 1 Cardiovascular Medicine
More informationRelation of Saphenous Vein Graft Obstruction to Serum Cholesterol Levels
JACC Vol. 25, No. 1 193 Janua~ 1995:193-7 Relation of Saphenous Vein Graft Obstruction to Serum Cholesterol Levels HIROYUKI DAIDA, MD, HISASHI YOKOI, MD, HIROSHI MIYANO, MD, HIROSHI MOKUNO, MD, HIROYUKI
More informationDiabetes, Diet and SMI: How can we make a difference?
Diabetes, Diet and SMI: How can we make a difference? Dr. Adrian Heald Consultant in Endocrinology and Diabetes Leighton Hospital, Crewe and Macclesfield Research Fellow, Manchester University Relative
More informationA: Epidemiology update. Evidence that LDL-C and CRP identify different high-risk groups
A: Epidemiology update Evidence that LDL-C and CRP identify different high-risk groups Women (n = 27,939; mean age 54.7 years) who were free of symptomatic cardiovascular (CV) disease at baseline were
More informationAtherosclerotic Disease Risk Score
Atherosclerotic Disease Risk Score Kavita Sharma, MD, FACC Diplomate, American Board of Clinical Lipidology Director of Prevention, Cardiac Rehabilitation and the Lipid Management Clinics September 16,
More informationDyslipidemia in the light of Current Guidelines - Do we change our Practice?
Dyslipidemia in the light of Current Guidelines - Do we change our Practice? Dato Dr. David Chew Soon Ping Senior Consultant Cardiologist Institut Jantung Negara Atherosclerotic Cardiovascular Disease
More informationDyslipidemia in women: Who should be treated and how?
Dyslipidemia in women: Who should be treated and how? Lale Tokgozoglu, MD, FACC, FESC Professor of Cardiology Hacettepe University Faculty of Medicine Ankara, Turkey. Cause of Death in Women: European
More informationDouble-blind comparative clinical trial of Abana and Simvastatin in Hyperlipidaemia
[Insertion in Stroke, Feb-Mar., 2002] Double-blind comparative clinical trial of Abana and Simvastatin in Hyperlipidaemia Venkataramaiah, H., M.D., D.M. (Cardiology), Professor of Cardiology, Jayadeva
More information2.5% of all deaths globally each year. 7th leading cause of death by % of people with diabetes live in low and middle income countries
Lipid Disorders in Diabetes (Diabetic Dyslipidemia) Khosrow Adeli PhD, FCACB, DABCC Head and Professor, Clinical Biochemistry, The Hospital for Sick Children, University it of Toronto Diabetes A Global
More informationHyperlipidemia and Cardiovascular Risk Factors in Patients With Type 2 Diabetes
...PRESENTATIONS... Hyperlipidemia and Cardiovascular Risk Factors in Patients With Type 2 Diabetes Based on a presentation by Ronald B. Goldberg, MD Presentation Summary Atherosclerosis accounts for approximately
More informationStatistical Fact Sheet Populations
Statistical Fact Sheet Populations At-a-Glance Summary Tables Men and Cardiovascular Diseases Mexican- American Males Diseases and Risk Factors Total Population Total Males White Males Black Males Total
More informationTotal risk management of Cardiovascular diseases Nobuhiro Yamada
Nobuhiro Yamada The worldwide burden of cardiovascular diseases (WHO) To prevent cardiovascular diseases Beyond LDL Multiple risk factors With common molecular basis The Current Burden of CVD CVD is responsible
More informationChanging lipid-lowering guidelines: whom to treat and how low to go
European Heart Journal Supplements (2005) 7 (Supplement A), A12 A19 doi:10.1093/eurheartj/sui003 Changing lipid-lowering guidelines: whom to treat and how low to go C.M. Ballantyne Section of Atherosclerosis,
More informationMetformin should be considered in all patients with type 2 diabetes unless contra-indicated
November 2001 N P S National Prescribing Service Limited PPR fifteen Prescribing Practice Review PPR Managing type 2 diabetes For General Practice Key messages Metformin should be considered in all patients
More informationJoint Effects of Serum Triglyceride and LDL Cholesterol and HDL Cholesterol Concentrations on Coronary Heart Disease Risk in the Helsinki Heart Study
37 Joint Effects of Serum Triglyceride and LDL Cholesterol and HDL Cholesterol Concentrations on Coronary Heart Disease Risk in the Helsinki Heart Study Implications for Treatment Vesa Manninen, MD; Leena
More informationLipid Management: A Case-Based Approach. Overview. Simple Lipid Therapy Approach. Patients have lipid disorders of:
Lipid Management: A Case-Based Approach Patrick E. McBride, M.D., M.P.H. Professor of Medicine, Cardiovascular Medicine Associate Director, Preventive Cardiology Program UW School of Medicine and Public
More information... CPE/CNE QUIZ... CPE/CNE QUESTIONS
CPE/CNE QUESTIONS Continuing Pharmacy Education Accreditation The Virginia Council on Pharmaceutical Education is approved by the American Council on Pharmaceutical Education as a provider of continuing
More informationPathophysiology of Lipid Disorders
Pathophysiology of Lipid Disorders Henry Ginsberg, M.D. Division of Preventive Medicine and Nutrition CHD in the United States CHD is the single largest killer of men and women 12 million have history
More informationPCSK9 Inhibitors and Modulators
PCSK9 Inhibitors and Modulators Pam R. Taub MD, FACC Director of Step Family Cardiac Rehabilitation and Wellness Center Associate Professor of Medicine UC San Diego Health System Disclosures Speaker s
More informationMedication compliance and serum lipid changes in the Helsinki
Br. J. clin. Pharmac. (1991), 32, 409415 Medication compliance and serum lipid changes in the Helsinki Heart Study HANNA MAENPAA, 0. P. HEINONEN & V. MANNINEN First Department of Medicine, University of
More informationClinical Recommendations: Patients with Periodontitis
The American Journal of Cardiology and Journal of Periodontology Editors' Consensus: Periodontitis and Atherosclerotic Cardiovascular Disease. Friedewald VE, Kornman KS, Beck JD, et al. J Periodontol 2009;
More informationCLINICAL OUTCOME Vs SURROGATE MARKER
CLINICAL OUTCOME Vs SURROGATE MARKER Statin Real Experience Dr. Mostafa Sherif Senior Medical Manager Pfizer Egypt & Sudan Objective Difference between Clinical outcome and surrogate marker Proper Clinical
More informationTitle for Paragraph Format Slide
Title for Paragraph Format Slide Presentation Title: Month Date, Year Atherosclerosis A Spectrum of Disease: February 12, 2015 Richard Cameron Padgett, MD Executive Medical Director, OHVI Pt RB Age 38
More informationHyperlipidemia: Lowering the Bar on the Lipid Limbo. Community Faculty Development Symposium March 13, 2004 Hugh Huizenga MD, MPH
Mark slides Hyperlipidemia: Lowering the Bar on the Lipid Limbo Community Faculty Development Symposium March 13, 2004 Hugh Huizenga MD, MPH Hyperlipidemia is a common problem Nearly 50% of men in the
More information2013 Hypertension Measure Group Patient Visit Form
Please complete the form below for 20 or more unique patients meeting patient sample criteria for the measure group for the current reporting year. A majority (11 or more) patients must be Medicare Part
More informationLow-density lipoprotein as the key factor in atherogenesis too high, too long, or both
Low-density lipoprotein as the key factor in atherogenesis too high, too long, or both Lluís Masana Vascular Medicine and Metabolism Unit. Sant Joan University Hospital. IISPV. CIBERDEM Rovira i Virgili
More informationLearning Objectives. Cholesterol and Lipids in Kids: It s a Matter of the Heart. Is Atherosclerosis a Pediatric Disease?
Scott J. Soifer, MD Professor and Vice Chair Department of Pediatrics University of California, San Francisco UCSF Benioff Children s Hospital Cholesterol and Lipids in Kids: It s a Matter of the Heart
More informationCombined effects of systolic blood pressure and serum cholesterol on cardiovascular mortality in young (<55 years) men and women
European Heart Journal (2002) 23, 528 535 doi:10.1053/euhj.2001.2888, available online at http://www.idealibrary.com on Combined effects of systolic blood pressure and serum cholesterol on cardiovascular
More informationLow-density lipoproteins cause atherosclerotic cardiovascular disease (ASCVD) 1. Evidence from genetic, epidemiologic and clinical studies
Low-density lipoproteins cause atherosclerotic cardiovascular disease (ASCVD) 1. Evidence from genetic, epidemiologic and clinical studies A Consensus Statement from the European Atherosclerosis Society
More informationATP III (Adult Treatment Panel III) CLASSIFICATION C IN ADULTS
LABORATORY AND RISK FACTORS OF ATHEROSCLEROSIS S R. Mohammadi Biochemist (Ph.D.) Faculty member of Medical Faculty RISK FACTORS FOR CHD Clinical Risk Factors Laboratory Risk Factors MAJOR CLINICAL RISK
More informationR E V I E W O F E V I D E N C E O N T H E E F F I C A C Y O F T R E A T M E N T O F H Y P E R L I P I D E M I A
T H E M E : H Y E R L I I D E M I A UNIT N. 2 A/rof Goh Lee Gan, Dr eter Yan Chee Hong INTRDUCTIN Total cholesterol was once implicated as the cause of CHD but it is now clear that it is the LDL cholesterol
More information10. HYPERLIPIDEMIA. Beatrice Golomb, MD, PhD
10. HYPERLIPIDEMIA Beatrice Golomb, MD, PhD The development of quality indicators for screening and treatment of hyperlipidemia was initially based on current guidelines and review articles on hyperlipidemia.
More information